Skip to content

Coronary Computed Tomographic Angiography in Intermediate-risk Chest Pain Patients

Randomized Evaluation of Coronary Computed Tomographic Angiography in Intermediate-risk Patients Presenting to the Emergency Department With Chest Pain

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04748237
Acronym
FAST-CCTA
Enrollment
1600
Registered
2021-02-10
Start date
2021-01-21
Completion date
2025-12-31
Last updated
2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Chest Pain, Coronary Artery Disease

Brief summary

The aim is to determine whether a diagnostic strategy including early coronary computed tomographic angiography in intermediate-risk patients presenting to the Emergency Department with chest pain reduces the composite endpoint of death, readmission because of myocardial infarction or unstable angina requiring revascularization.

Detailed description

Patients presenting to the ED with chest pain or other symptoms suggestive of ACS, without acute MI but with an intermediate risk (HEART-score \>3) will after written informed consent be randomized to either a strategy with an initial CCTA or not. Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and perform a CCTA as soon as possible (in most cases within 24 hours, but at least within 21 days).The result will be presented to the responsible physician who will plan further care of the patients. Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always. All patients should receive optimal prevention according to current guidelines. The responsible physician will be encouraged to initiate secondary prevention measures if examinations show signs of CAD. The primary endpoint is composite of death, readmission because of MI or unstable angina requiring revascularization.

Interventions

DIAGNOSTIC_TESTCoronary computed tomopraphic angiography

CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Masking description

Before adjudication, all documents will be masked regarding previous coronary computed tomographic angiography.

Intervention model description

Patients presenting to the ED with chest pain or other symptoms suggestive of ACS, without acute MI but with an intermediate risk (HEART-score \>3) will after written informed consent be randomized to either a strategy with an initial coronary computed tomographic angiography or not.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age≥18 years. 2. Within 24 hours from presenting to the ED with chest pain or other symptoms suggestive of coronary artery disease (CAD) 3. HEART-score \>3 (according to http://www.heartscore.nl/) 4. Written informed consent obtained

Exclusion criteria

1. Any condition that may influence the patient's ability to comply with study protocol. 2. Acute MI 3. Known obstructive CAD (\>50%) or previous PCI or CABG. 4. Clear alternative diagnosis 5. Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 6. Major allergy to iodinated contrast media 7. Circumstances making high quality images unlikely. 8. Not a Swedish resident with a personal ID-number. 9. Pregnancy or breast feeding 10. Further investigation for CAD not indicated, due to limited life expectancy, quality of life or functional status 11. Previous inclusion in the trial

Design outcomes

Primary

MeasureTime frameDescription
The composite of death, readmission because of MI or unstable angina requiring revascularizationthrough study completion, an average of 5 yeardeath of any cause, readmission because of MI (I21) or revascularization because of unstable angina not related to the index event

Secondary

MeasureTime frameDescription
Deaththrough study completion, an average of 5 yeardeath of any cause
Cardiovascular deaththrough study completion, an average of 5 yeardeath because of cardiovascular cause (I00-99)
MI (fatal or non-fatal)through study completion, an average of 5 yearreadmission because of MI or death because of MI (I21)
Readmission because of unstable angina requiring revascularizationthrough study completion, an average of 5 yearrevascularization because of unstable angina not related to the index event.
Death, readmission because MI or strokethrough study completion, an average of 5 yeardeath of any cause, readmission because of MI (I21) or stroke (I61-I64)
Stroke (fatal or non-fatal)through study completion, an average of 5 yearreadmission because of stroke (I61-I64) or death because of stroke (I61-I64)
Death or readmission because MIthrough study completion, an average of 5 yeardeath of any cause, readmission because of MI (I21)
Re-presentation to the ED because of chest painthrough study completion, an average of 5 yearRe-presentation with chest pain as the main complaint
Invasive coronary angiographythrough study completion, an average of 5 yearAny invasive coronary angiography
Non-obstructive CAD at first invasive coronary angiographythrough study completion, an average of 5 yearInvasive coronary angiography without any significant stenoses
Angina1 yearat least grade 1 according to Rose questionnaire
Use of prevention medications1, 2 and 3 yearsUse (dispensed prescriptions) of prevention medications (antiplatelet therapy, Statins, blood pressure lowering therapy)
Health-related quality of life1 yearRAND-36: 8 domains/scales
Resource use / Health care coststhrough study completion, an average of 5 yearHospitalizations and investigations

Countries

Sweden

Contacts

Primary ContactLiselotte Persson, RN
Liselotte.Persson@sll.se+46812355000
Backup ContactHenrik Löfmark, MD
Henrik.Lofmark@sll.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026